Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges.

ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease in industrialized economies. With no licensed treatment currently available, together with a growing prevalence that parallels global increases in obesity and type 2 diabetes, NAFLD will dominate the landscape of hepatology for the foreseeable future. A multifaceted etiopathogenesis, paucity of reproducible preclinical models that effectively recreate human NAFLD, and lack of robust surrogate trial endpoints have presented major hurdles in drug discovery and development. Smooth collaboration between bench scientists, biotechnology, pharmaceutical industries, and clinicians will be pivotal to target identification, development of effective therapies, biomarker discovery, and ultimately to bring pipeli

SUBMITTER: Thiagarajan P 

PROVIDER: S-EPMC6728526 | biostudies-literature | 2019 Jul-Aug

REPOSITORIES: biostudies-literature